Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas

Cancer

Volumn 118, Issue 23, 2012, Pages 5840-5847

  Paik, Paul K ^a,b   Johnson, Melissa L ^c   D'Angelo, Sandra P ^a,b   Sima, Camelia S ^a   Ang, Daphne ^d   Dogan, Snjezana ^a   Miller, Vincent A ^a,b   Ladanyi, Marc ^a   Kris, Mark G ^a,b   Riely, Gregory J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

adenocarcinoma; anaplastic lymphoma kinase; epidermal growth factor; never smoker; nonsmall cell lung cancer; v Ki ras2 Kirsten rat sarcoma viral oncogene homolog

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN;

ADULT; AGED; ALK GENE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; EGFR GENE; FEMALE; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; GENETIC VARIABILITY; GENOTYPE; HUMAN; KARNOFSKY PERFORMANCE STATUS; KRAS GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 84869505060     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27637     Document Type: Article

References (28)

1. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 2149-2158. (Pubitemid 37432975)
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132. (Pubitemid 41058344)
3. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527-1537. (Pubitemid 41540110)
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139. (Pubitemid 38637993)
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500. (Pubitemid 38720929)
6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311. (Pubitemid 39209661)
7. Kris M, Lau CY, Ang D, et al. Initial results of LC-MAP: an institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma [abstract]. J Clin Oncol. 2010; 28 (15S). Abstract 7009.
8. Riely GJ, Marks J, Pao W,. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009; 6: 201-205.
9. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566. (Pubitemid 47206930)
10. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24: 5034-5042. (Pubitemid 46631407)
11. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008; 14: 5731-5734.
12. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27: 4247-4253.
13. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
14. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
15. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
16. Janjigian YY, McDonnell K, Kris MG, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2010; 116: 670-675.
17. Pan Q, Pao W, Ladanyi M,. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005; 7: 396-403. (Pubitemid 41149655)
18. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [serial online]. PLoS Med. 2005; 2: e17.
19. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006; 24: 1700-1704. (Pubitemid 46622141)
20. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3: 13-17.
21. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17: 889-897.
22. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010; 465: 473-477.
23. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12: 1004-1012.
24. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011; 29: 2046-2051.
25. Arcila M, Chaft J, Nafa K, Kris M, Zakowski M, Ladanyi M,. Molecular and clinicopathologic characteristics of HER2-mutant lung adenocarcinoma (ADC). J Clin Oncol. 2011; 29 (suppl). Abstract 10596.
26. Pietanza M, Arcila M, Chaft J, et al. Clinical, pathologic, and molecular characteristics of patients with non-small cell lung cancer harboring mutations in PIK3CA [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract 7587.
27. Kris M,. The Lung Cancer Mutation Consortium. Paper presented at: International Association for the Study of Lung Cancer (IASLC) 12th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting; February 22-25, 2012; Santa Monica, Calif.
28. Toh C-K, Gao F, Lim W-T, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006; 24: 2245-2251. (Pubitemid 46630653)